CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Li, Li ^a,b   Yan, Jing ^b   Xu, Jing ^b   Liu, Chao Qun ^b   Zhen, Zuo Jun ^a   Chen, Huan Wei ^a   Ji, Yong ^a   Wu, Zhi Peng ^a   Hu, Jian Yuan ^a   Zheng, Limin ^b   Lau, Wan Yee ^a,c  

^a THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD68 ANTIGEN; CHEMOKINE; CXCL17 CHEMOKINE; UNCLASSIFIED DRUG; CXCL17 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NEUTROPHIL CHEMOTAXIS; OVERALL SURVIVAL; PATIENT CODING; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; CANCER GRADING; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; FOLLOW UP; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RECURRENCE; TUMOR VOLUME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOKINES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR BURDEN; YOUNG ADULT;

EID: 84907830903     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110064     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69-90.
2. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nature Reviews Gastroenterology and Hepatology 7: 448-458.
3. Poon D, Anderson BO, Chen L-T, Tanaka K, Lau WY, et al. (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. The lancet oncology 10: 1111-1118.
4. Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
5. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, et al. (2010) New strategies in hepatocellular carcinoma: genomic prognostic markers. Clinical Cancer Research 16: 4688-4694.
6. Kuang D-M, Zhao Q, Peng C, Xu J, Zhang J-P, et al. (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. The Journal of experimental medicine 206: 1327-1337.
7. Kuang D-M, Zhao Q, Wu Y, Peng C, Wang J, et al. (2011) Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. Journal of hepatology 54: 948-955.
8. Bjorkstrom NK, Ljunggren HG, Sandberg JK (2010) CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol 31: 401-406.
9. Balkwill F (2004) Cancer and the chemokine network. Nature Reviews Cancer 4: 540-550.
10. Mishra P, Banerjee D, Ben-Baruch A (2011) Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. Journal of leukocyte biology 89: 31-39.
11. Mantovani A (2009) The yin-yang of tumor-associated neutrophils. Cancer cell 16: 173-174.
12. Lazennec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends in molecular medicine 16: 133-144.
13. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P (2007) Role of chemokines in endocrine autoimmune diseases. Endocrine reviews 28: 492-520.
14. Abastado JP (2012) The next challenge in cancer immunotherapy: controlling Tcell traffic to the tumor. Cancer Res 72: 2159-2161.
15. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, et al. (2012) Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 56: 2242-2254.
16. Gao Q, Zhao Y-J, Wang X-Y, Qiu S-J, Shi Y-H, et al. (2012) CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer research 72: 3546-3556.
17. Weinstein EJ, Head R, Griggs DW, Sun D, Evans RJ, et al. (2006) VCC-1, a novel chemokine, promotes tumor growth. Biochemical and biophysical research communications 350: 74-81.
18. Pisabarro MT, Leung B, Kwong M, Corpuz R, Frantz GD, et al. (2006) Cutting edge: novel human dendritic cell-and monocyte-attracting chemokine-like protein identified by fold recognition methods. The Journal of Immunology 176: 2069-2073.
19. Mu X, Chen Y, Wang S, Huang X, Pan H, et al. (2009) Overexpression of VCC-1 gene in human hepatocellular carcinoma cells promotes cell proliferation and invasion. Acta biochimica et biophysica Sinica 41: 631-637.
20. Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, et al. (2011) CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 140: 310-321. e314.
21. Zhou Z, Lu X, Zhu P, Zhu W, Mu X, et al. (2012) VCC-1 over-expression inhibits cisplatin-induced apoptosis in HepG2 cells. Biochemical and biophysical research communications 420: 336-342.
22. Xu J, Ding T, He Q, Yu X-J, Wu W-C, et al. (2012) An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. Journal of hepatology 57: 313-321.
23. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35: 519-524.
24. Gao Q, Qiu S-J, Fan J, Zhou J, Wang X-Y, et al. (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. Journal of Clinical Oncology 25: 2586-2593.
25. Ding T, Xu J, Zhang Y, Guo RP, Wu WC, et al. (2011) Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection. Cancer 117: 4878-4889.
26. Huang W, Hennrick K, Drew S (2013) A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Human pathology 44: 29-38.
27. Nicholson TM, Sehgal PD, Drew SA, Huang W, Ricke WA (2013) Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment. Differentiation 85: 140-149.
28. Abel EJ, Bauman TM, Weiker M, Shi F, Downs TM, et al. (2014) Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high throughput evaluation of protein expression. Human pathology. 45: 1092-1099.
29. Zhang J-P, Yan J, Xu J, Pang X-H, Chen M-S, et al. (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. Journal of hepatology 50: 980-989.
30. Ding T, Xu J, Wang F, Shi M, Zhang Y, et al. (2009) High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Human pathology 40: 381-389.
31. Li Y-W, Qiu S-J, Fan J, Zhou J, Gao Q, et al. (2011) Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. Journal of hepatology 54: 497-505.
32. Galon J, Angell HK, Bedognetti D, Marincola FM (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39: 11-26.
33. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.
34. Huang F, Geng X-P (2010) Chemokines and hepatocellular carcinoma. World journal of gastroenterology: WJG 16: 1832.
35. Matsui A, Yokoo H, Negishi Y, Endo-Takahashi Y, Chun NA, et al. (2012) CXCL17 Expression by Tumor Cells Recruits CD11b+ Gr1highF4/80- Cells and Promotes Tumor Progression. PLoS One 7: e44080.
36. Zhu X-D, Zhang J-B, Zhuang P-Y, Zhu H-G, Zhang W, et al. (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. Journal of Clinical Oncology 26: 2707-2716.
37. Shirabe K, Mano Y, Muto J, Matono R, Motomura T, et al. (2012) Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surgery today 42: 1-7.
38. Sica A, Larghi P, Mancino A, Rubino L, Porta C, et al. (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18: 349-355.
39. Kuang D-M, Wu Y, Chen N, Cheng J, Zhuang S-M, et al. (2007) Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 110: 587-595.
40. Lee W-Y, Wang C-J, Lin T-Y, Hsiao C-L, Luo C-W (2013) CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor. American journal of physiology Endocrinology and metabolism 304: E32-40.
41. Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nature Reviews Cancer 12: 298-306.
42. Yan J, Zhang Y, Zhang J-P, Liang J, Li L, et al. (2013) Tim-3 expression defines regulatory T cells in human tumors. PLoS One 8: e58006.